All In Biotech

Drug Trial Radar · NCT02970305

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

Last checked: Nov 20, 2026Latest source record: Dec 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 403 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

403

Actual

Start

Nov 4, 2016

Primary completion

Oct 16, 2019

Study completion Oct 28, 2019

Sponsor

Lead sponsor
ACADIA Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Nov 22, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of the negative symptoms of schizophrenia

Conditions

  • Schizophrenia

Interventions

  • PimavanserinDrug

    Pimavanserin 34 mg, 20 mg, or 10 mg, taken as two tablets, once daily by mouth

  • PlaceboDrug

    Placebo, taken as two tablets, once daily by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 26 in the Negative Symptom Assessment-16 (NSA-16) Total ScoreTime frame: From baseline to Week 26

Locations

101 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Rogers, Arkansas

  • Site not named

    Bellflower, California

  • Site not named

    Lemon Grove, California

  • Site not named

    Norwalk, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    Santa Ana, California

  • Site not named

    Torrance, California

  • Site not named

    Hialeah, Florida

  • Site not named

    Lauderhill, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Marietta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Hoffman Estates, Illinois

  • Site not named

    Wichita, Kansas

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Berlin, New Jersey

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Rochester, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Durham, North Carolina

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Downingtown, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Irving, Texas

  • Site not named

    Richardson, Texas

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Targovishte, Bulgaria

  • Site not named

    Tserova Koria, Bulgaria

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.